表在性膀胱腫瘍に対するBCG膀胱内注入療法の再発予防効果に関する検討

Abstract

表在性膀胱腫瘍39例に対しBCG膀胱内注入療法を施行した。1) 6回以下の注入群と非注入群において実測非再発率はそれぞれ41.0%と38.3%で, 有意差はなかった。2) 7回以上の注入群は94.0%という高い非再発率であった。3) BCGは膀注回数を重ねることでかなり高い非再発率をえられると考えられた

Intracavitary instillation of Tokyo 172 strain Bacillas Calmette-Guerin was performed on 39 patients with superficial bladder cancer after contact Nd:YAG laser irradiation for tumors. The BCG group received intravesical instillation of 80 mg BCG at two week intervals for 6 months. Recurrence occurred in 7 of the 39 patients. In the 7 recurrent cases instillation of BCG had been discontinued after 2-7 instillations due to bladder irritation, with recurrence seen 6-27 months later. The non-recurrence rate in the group (27 cases) instilled BCG more than seven times was 94.0%. The non-recurrence rate in this group was significantly higher than that in the group (12 cases) with less than six BCG instillations. The non-recurrence rate in the group (26 cases) without BCG therapy was not significantly different from that in the group (12 cases) with less than six BCG instillations. Our findings suggested that frequent (more than seven times) instillation of BCG increased the non-recurrence rate, and that less than six BCG instillations is not significantly effective for preventing the recurrence of superficial bladder cancer.